Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.
Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.
The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.
With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a webcast and conference call scheduled for February 4, 2021, at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ending December 31, 2020. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days post-call. Arrowhead specializes in developing RNA interference-based therapeutics targeting intractable diseases through innovative gene silencing techniques.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced inducement grants for 27 new employees, approved on December 4, 2020. The grants include options to purchase 145,000 shares at a strike price of $65.29 and the potential for 96,000 restricted stock units (RSUs). These grants are outside the stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on RNA interference therapies targeting intractable diseases, leveraging gene silencing to effectively treat conditions.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in key upcoming events. The Piper Sandler 32nd Annual Virtual Healthcare Conference occurs from December 1-3, 2020, featuring a presentation by CEO Chris Anzalone on December 2. Additionally, at the 20th Gordon L. Snider Critical Issues Workshop on December 12, James Hamilton, M.D., will discuss Arrowhead’s gene silencing approach for liver disease in Alpha-1 antitrypsin deficiency. Webcast links and materials are accessible on the company's Events and Presentations page.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the collaboration and license agreement with Takeda Pharmaceutical Company Limited has officially closed. This closing was contingent upon review under U.S. antitrust laws, including the Hart-Scott-Rodino Act. Arrowhead focuses on developing RNA interference-based therapies to treat intractable diseases, leveraging its portfolio of RNA chemistries for gene silencing.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported fiscal year 2020 results showing a significant revenue decline to $87.99 million from $168.80 million in 2019. The operating loss widened to $93.16 million, with a net loss of $84.55 million, translating to a diluted loss per share of $0.84. However, the company received a $20 million milestone from Amgen and achieved a strategic partnership with Takeda, including $300 million upfront and up to $740 million in milestones. Cash resources increased to $452.98 million, bolstering its financial position despite operating challenges.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced promising clinical data from its cardiometabolic pipeline at the AHA Scientific Sessions 2020. The company's investigational products, ARO-ANG3 and ARO-APOC3, showed strong responses in lipid parameters, addressing persistent cardiovascular risks. Notable presentations include pharmacodynamic effects targeting hypercholesterolemia and hypertriglyceridemia. Webinars on November 18 and 19 will further discuss these findings and future plans. These advancements position Arrowhead favorably in the competitive landscape of cardiovascular therapeutics.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announces positive interim results from its Phase 2 study AROAAT2002, evaluating ARO-AAT for treating alpha-1 antitrypsin deficiency (AATD). Patients receiving three doses showed significant reductions in the disease-causing Z-AAT protein, with serum reductions of 86-93% and liver reductions up to 95%. Improvements were noted in liver health biomarkers. The study indicates potential for accelerated regulatory discussions as further patient data is expected in the coming months.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to participate in significant upcoming medical events. From November 13-16, 2020, at the Liver Meeting Digital Experience, they will present findings on ARO-AAT's effectiveness in reducing Z-AAT protein in patients with liver disease. At the AHA Scientific Sessions (November 13-17, 2020), the company will showcase multiple studies, including ARO-ANG3 and ARO-APOC3, targeting hypercholesterolemia and hypertriglyceridemia. CEO Chris Anzalone will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will host two webinars on November 18 and 19, 2020, focusing on its investigational RNA interference (RNAi) candidates ARO-APOC3 and ARO-ANG3. Key opinion leaders, Christie Ballantyne, M.D., and Ira Goldberg, M.D., will present on the unmet medical needs in treating hypertriglyceridemia and mixed dyslipidemia, respectively. Data from Phase 1/2 clinical studies for both candidates will also be presented at the American Heart Association's Scientific Sessions 2020. The webinars will be accessible through the company's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a conference call and webcast on November 23, 2020, at 4:30 p.m. EST to discuss its fiscal year 2020 financial results ending September 30. Investors can access the live event on the company’s website, with replay options available post-call. Arrowhead focuses on RNA interference-based therapeutics targeting serious diseases by silencing specific genes. The company aims to leverage its RNA chemistry portfolio to develop innovative treatments.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
What is the primary focus of Arrowhead Pharmaceuticals?
What is RNA interference (RNAi)?
What is the TRiMTM platform?
Which diseases does Arrowhead Pharmaceuticals address?
Where is Arrowhead Pharmaceuticals headquartered?
What are the latest developments at Arrowhead Pharmaceuticals?
How does Arrowhead's technology benefit patients?
What are some advantages of the TRiMTM platform?
Is Arrowhead publicly traded?
How can I invest in Arrowhead Pharmaceuticals?
